Flunisolide Suppliers & Bulk Manufacturers
Available Forms: Inhalation solution
Available Strengths: 250 mcg
Reference Brands: AeroBid (USA)
Category:
Respiratory Disorder
Flunisolide is available in Inhalation solution
and strengths such as 250 mcg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Flunisolide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Flunisolide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Flunisolide is a synthetic corticosteroid commonly prescribed for the treatment of allergic rhinitis and other inflammatory conditions of the nasal passages. It is marketed under brand names such as AeroBid and is primarily administered as an intranasal spray. Intranasal corticosteroids, including flunisolide, are considered the most effective therapeutic option for controlling nasal symptoms such as congestion, sneezing, itching, and rhinorrhea associated with allergic rhinitis.
The principal mechanism of action of flunisolide involves activation of glucocorticoid receptors, resulting in potent anti-inflammatory effects. By reducing the release of inflammatory mediators and suppressing local immune responses, flunisolide helps decrease swelling and irritation of the nasal mucosa. As a topical corticosteroid, its therapeutic effects are not immediate, and consistent daily use for several days is required to achieve noticeable symptom relief. Intermittent or as-needed use is less effective compared to regular administration as prescribed.
Flunisolide is intended for long-term symptom control rather than rapid relief. It should not be used in the presence of untreated nasal infections. If symptoms do not improve after two to three weeks of regular use, continued treatment is not recommended, and clinical reassessment may be necessary.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing